{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:29:22Z","timestamp":1758634162666},"reference-count":65,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>With the application of modern chemotherapy and radiation techniques, most patients with Hodgkin lymphoma can be cured, regardless of initial extent of disease. However, the lymphoma sometimes presents coincident with certain other major conditions, including pregnancy, infection with human immunodeficiency virus (HIV) or older age, which complicate treatment and make management considerably more challenging. Specially crafted approaches to staging and treatment, including the addition of specific supportive care measures, are required in these situations. Pregnant patients with coincident Hodgkin lymphoma should be staged without the use of imaging requiring radiation and treated with an approach that includes initial treatment deferral when appropriate, single agent vinblastine and reservation of multi-agent chemotherapy for the small minority with very aggressive lymphoma. Patients with Hodgkin lymphoma and HIV infection can be given standard anti-lymphoma treatment but require intensive supportive care with highly active anti-retroviral treatment (HAART) and prophylactic anti-fungal and anti-Pneumocystis antibiotics plus neutrophil growth factors. Standard staging and full dose multi-agent chemotherapy are necessary if older patients with Hodgkin lymphoma are to be afforded the best chance of cure but the final choice of the individual elements of treatment must respect co-morbid conditions and age- or other disease-related organ compromise. If appropriately chosen, these special measures permit delivery of safe, effective treatment and frequent cure of the Hodgkin lymphoma despite complicating pregnancy, HIV infection or older age.<\/jats:p>","DOI":"10.1182\/asheducation-2008.1.334","type":"journal-article","created":{"date-parts":[[2008,12,11]],"date-time":"2008-12-11T15:12:58Z","timestamp":1229008378000},"page":"334-339","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Challenging Problems: Coincident Pregnancy, HIV Infection, and Older Age"],"prefix":"10.1182","volume":"2008","author":[{"given":"Joseph M.","family":"Connors","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111708422702800_R1","doi-asserted-by":"crossref","unstructured":"Lishner M, Zemlickis D, Degendorfer P, Panzarella T, Sutcliffe SB, Koren G. Maternal and foetal outcome following Hodgkin\u2019s disease in pregnancy. Br J Cancer. 1992;65:114\u2013117.","DOI":"10.1038\/bjc.1992.21"},{"key":"2019111708422702800_R2","doi-asserted-by":"crossref","unstructured":"Aviles A, Neri N. Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. Clin Lymphoma. 2001;2:173\u2013177.","DOI":"10.3816\/CLM.2001.n.023"},{"key":"2019111708422702800_R3","doi-asserted-by":"crossref","unstructured":"Ebert U, Loffler H, Kirch W. Cytotoxic therapy and pregnancy [review]. Pharmacol Ther. 1997;74:207\u2013220.","DOI":"10.1016\/S0163-7258(97)82004-9"},{"key":"2019111708422702800_R4","unstructured":"Gobbi PG, Attardo-Parrinello A, Danesino M, et al. Hodgkin\u2019s disease and pregnancy. Haematologica. 1984;69:336\u2013341."},{"key":"2019111708422702800_R5","doi-asserted-by":"crossref","unstructured":"Nisce LZ, Tome MA, He S, Lee BJ, 3rd, Kutcher GJ. Management of coexisting Hodgkin\u2019s disease and pregnancy. Am J Clin Oncol. 1986;9:146\u2013151.","DOI":"10.1097\/00000421-198604000-00009"},{"key":"2019111708422702800_R6","doi-asserted-by":"crossref","unstructured":"Gelb AB, van de Rijn M, Warnke RA, Kamel OW. Pregnancy-associated lymphomas. A clinicopathologic study. Cancer. 1996;78:304\u2013310.","DOI":"10.1002\/(SICI)1097-0142(19960715)78:2<304::AID-CNCR18>3.0.CO;2-#"},{"key":"2019111708422702800_R7","doi-asserted-by":"crossref","unstructured":"Thomas PR, Peckham MJ. The investigation and management of Hodgkin\u2019s disease in the pregnant patient. Cancer. 1976;38:1443\u20131451.","DOI":"10.1002\/1097-0142(197609)38:3<1443::AID-CNCR2820380352>3.0.CO;2-D"},{"key":"2019111708422702800_R8","unstructured":"Tawil E, Mercier JP, Dandavino A. Hodgkin\u2019s disease complicating pregnancy. J Can Assoc Radiol. 1985;36:133\u2013137."},{"key":"2019111708422702800_R9","doi-asserted-by":"crossref","unstructured":"Anselmo AP, Cavalieri E, Enrici RM, Pescarmona E, Guerrisi V, Paesano R, et al. Hodgkin\u2019s disease during pregnancy: diagnostic and therapeutic management. Fetal Diagn Ther. 1999;14:102\u2013105.","DOI":"10.1159\/000020898"},{"key":"2019111708422702800_R10","doi-asserted-by":"crossref","unstructured":"Byram D, Foulstone P. Radiotherapy for Hodgkin\u2019s disease in pregnancy. Australas Radiol. 1997;41:407\u2013408.","DOI":"10.1111\/j.1440-1673.1997.tb00744.x"},{"key":"2019111708422702800_R11","doi-asserted-by":"crossref","unstructured":"Leung JT, Kuan R, Patel V. Radiotherapy for Hodgkin\u2019s disease in pregnancy. Australas Radiol. 1996;40:146\u2013148.","DOI":"10.1111\/j.1440-1673.1996.tb00369.x"},{"key":"2019111708422702800_R12","doi-asserted-by":"crossref","unstructured":"Armstrong JG, Dyke RW, Fouts PJ. Vinblastine sulfate treatment of Hodgkin\u2019s disease during a pregnancy. Science. 1964;143:703.","DOI":"10.1126\/science.143.3607.703"},{"key":"2019111708422702800_R13","doi-asserted-by":"crossref","unstructured":"Lacher MJ. Use of vinblastine sulfate to treat Hodgkin\u2019s disease during pregnancy. Ann Intern Med. 1964;61:113\u2013115.","DOI":"10.7326\/0003-4819-61-1-113"},{"key":"2019111708422702800_R14","doi-asserted-by":"crossref","unstructured":"Rosenzweig AI, Crews QE, Jr., Hopwood HG. Vinblastine sulfate in Hodgkin\u2019s disease in pregnancy. Ann Intern Med. 1964;61:108\u2013112.","DOI":"10.7326\/0003-4819-61-108"},{"key":"2019111708422702800_R15","doi-asserted-by":"crossref","unstructured":"Berenguer J, Miralles P, Ribera JM, et al. Characteristics and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47:422\u2013428.","DOI":"10.1097\/QAI.0b013e31815e722b"},{"key":"2019111708422702800_R16","doi-asserted-by":"crossref","unstructured":"Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA. Hodgkin lymphoma and immunodeficiency in persons with HIV\/AIDS. Blood. 2006;108:3786\u20133791.","DOI":"10.1182\/blood-2006-05-024109"},{"key":"2019111708422702800_R17","doi-asserted-by":"crossref","unstructured":"Rapezzi D, Ugolini D, Ferraris AM, Racchi O, Gaetani GF. Histological subtypes of Hodgkin\u2019s disease in the setting of HIV infection. Ann Hematol. 2001;80:340\u2013344.","DOI":"10.1007\/s002770100294"},{"key":"2019111708422702800_R18","doi-asserted-by":"crossref","unstructured":"Tirelli U, Errante D, Dolcetti R, et al. Hodgkin\u2019s disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. J Clin Oncol. 1995;13:1758\u20131767.","DOI":"10.1200\/JCO.1995.13.7.1758"},{"key":"2019111708422702800_R19","doi-asserted-by":"crossref","unstructured":"Dolcetti R, Boiocchi M, Gloghini A, Carbone A. Pathogenetic and histogenetic features of HIV-associated Hodgkin\u2019s disease. Eur J Cancer. 2001;37:1276\u20131287.","DOI":"10.1016\/S0959-8049(01)00105-8"},{"key":"2019111708422702800_R20","doi-asserted-by":"crossref","unstructured":"Powles T, Bower M. HIV-associated Hodgkin\u2019s disease. Int J STD AIDS. 2000;11:492\u2013494.","DOI":"10.1258\/0956462001916362"},{"key":"2019111708422702800_R21","doi-asserted-by":"crossref","unstructured":"Levine AM, Li P, Cheung T, et al. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin\u2019s disease: a prospective, multi- institutional AIDS clinical trials group study (ACTG 149). J Acquir Immune Defic Syndr. 2000;24:444\u2013450.","DOI":"10.1097\/00042560-200008150-00009"},{"key":"2019111708422702800_R22","doi-asserted-by":"crossref","unstructured":"Tanaka PY, Pessoa VP, Jr., Pracchia LF, Buccheri V, Chamone DA, Calore EE. Hodgkin lymphoma among patients infected with HIV in post-HAART era. Clin Lymphoma Myeloma. 2007;7:364\u2013368.","DOI":"10.3816\/CLM.2007.n.014"},{"key":"2019111708422702800_R23","doi-asserted-by":"crossref","unstructured":"Thompson LD, Fisher SI, Chu WS, Nelson A, Abbondanzo SL. HIV-associated Hodgkin lymphoma: a clinicopathologic and immunophenotypic study of 45 cases. Am J Clin Pathol. 2004;121:727\u2013738.","DOI":"10.1309\/PNVQ0PQGXHVY6L7G"},{"key":"2019111708422702800_R24","doi-asserted-by":"crossref","unstructured":"Errante D, Gabarre J, Ridolfo AL, et al. Hodgkin\u2019s disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF. Ann Oncol. 1999;10:189\u2013195.","DOI":"10.1023\/A:1008338915945"},{"key":"2019111708422702800_R25","doi-asserted-by":"crossref","unstructured":"Karcher DS. Clinically unsuspected Hodgkin disease presenting initially in the bone marrow of patients infected with the human immunodeficiency virus. Cancer. 1993;71:1235\u20131238.","DOI":"10.1002\/1097-0142(19930215)71:4<1235::AID-CNCR2820710411>3.0.CO;2-4"},{"key":"2019111708422702800_R26","doi-asserted-by":"crossref","unstructured":"Gastaldi R, Martino P, Gentile G, et al. Hodgkin\u2019s disease in HIV-infected patients: report of eight cases usefully treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) plus granulocyte colony-stimulating factor. Ann Oncol. 2002;13:1158\u20131160.","DOI":"10.1093\/annonc\/mdf239"},{"key":"2019111708422702800_R27","doi-asserted-by":"crossref","unstructured":"Xicoy B, Ribera JM, Miralles P, et al. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin\u2019s lymphoma. Haematologica. 2007;92:191\u2013198.","DOI":"10.3324\/haematol.10479"},{"key":"2019111708422702800_R28","doi-asserted-by":"crossref","unstructured":"Hartmann P, Rehwald U, Salzberger B, Franzen C, Sieber M, Wohrmann A, et al. BEACOPP therapeutic regimen for patients with Hodgkin\u2019s disease and HIV infection. Ann Oncol. 2003;14:1562\u20131569.","DOI":"10.1093\/annonc\/mdg408"},{"key":"2019111708422702800_R29","doi-asserted-by":"crossref","unstructured":"Gerard L, Galicier L, Boulanger E, et al. Improved survival in HIV-related Hodgkin\u2019s lymphoma since the introduction of highly active antiretroviral therapy. AIDS. 2003;17:81\u201387.","DOI":"10.1097\/00002030-200301030-00011"},{"key":"2019111708422702800_R30","doi-asserted-by":"crossref","unstructured":"Spina M, Gabarre J, Rossi G, et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood. 2002;100:1984\u20131988.","DOI":"10.1182\/blood-2002-03-0989"},{"key":"2019111708422702800_R31","doi-asserted-by":"crossref","unstructured":"Marti-Carvajal AJ, Cardona AF, Rodriguez ML. Interventions for treating AIDS-associated Hodgkin s lymphoma in treatment-naive adults. Cochrane Database Syst Rev.2007(2):CD006149.","DOI":"10.1002\/14651858.CD006149.pub2"},{"key":"2019111708422702800_R32","doi-asserted-by":"crossref","unstructured":"Hentrich M, Maretta L, Chow KU, et al. Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin\u2019s disease: results of a multicenter study. Ann Oncol. 2006;17:914\u2013919.","DOI":"10.1093\/annonc\/mdl063"},{"key":"2019111708422702800_R33","doi-asserted-by":"crossref","unstructured":"Vilchez RA, Finch CJ, Jorgensen JL, Butel JS. The clinical epidemiology of Hodgkin lymphoma in HIV-infected patients in the highly active antiretroviral therapy (HAART) era. Medicine (Baltimore). 2003;82:77\u201381.","DOI":"10.1097\/00005792-200303000-00001"},{"key":"2019111708422702800_R34","doi-asserted-by":"crossref","unstructured":"Ribera JM, Navarro JT, Oriol A, et al. Prognostic impact of highly active antiretroviral therapy in HIV- related Hodgkin\u2019s disease. AIDS. 2002;16:1973\u20131976.","DOI":"10.1097\/00002030-200209270-00020"},{"key":"2019111708422702800_R35","doi-asserted-by":"crossref","unstructured":"McNeil C. HIV infection with Hodgkin\u2019s disease: the virus makes a difference. J Natl Cancer Inst. 1997;89:754\u2013755.","DOI":"10.1093\/jnci\/89.11.754"},{"key":"2019111708422702800_R36","doi-asserted-by":"crossref","unstructured":"Vaughan Hudson B, MacLennan KA, Easterling MJ, Jelliffe AM, Haybittle JL, Vaughan Hudson G. The prognostic significance of age in Hodgkin\u2019s disease: examination of 1500 patients (BNLI report no. 23). Clin Radiol. 1983;34:503\u2013506.","DOI":"10.1016\/S0009-9260(83)80150-0"},{"key":"2019111708422702800_R37","doi-asserted-by":"crossref","unstructured":"Rossi Ferrini P, Bosi A, Casini C, Messori A, Bellesi G. Hodgkin\u2019s disease in the elderly: a retrospective clinicopathologic study of 61 patients aged over 60 years. Acta Haematol. 1987;78 Suppl 1:163\u2013170.","DOI":"10.1159\/000205924"},{"key":"2019111708422702800_R38","doi-asserted-by":"crossref","unstructured":"Specht L, Nissen NI. Hodgkin\u2019s disease and age. Eur J Haematol. 1989;43:127\u2013135.","DOI":"10.1111\/j.1600-0609.1989.tb00268.x"},{"key":"2019111708422702800_R39","doi-asserted-by":"crossref","unstructured":"Walker A, Schoenfeld ER, Lowman JT, Mettlin CJ, MacMillan J, Grufferman S. Survival of the older patient compared with the younger patient with Hodgkin\u2019s disease. Influence of histologic type, staging, and treatment. Cancer. 1990;65:1635\u20131640.","DOI":"10.1002\/1097-0142(19900401)65:7<1635::AID-CNCR2820650730>3.0.CO;2-M"},{"key":"2019111708422702800_R40","doi-asserted-by":"crossref","unstructured":"Enblad G, Glimelius B, Sundstrom C. Treatment outcome in Hodgkin\u2019s disease in patients above the age of 60: a population-based study. Ann Oncol. 1991;2:297\u2013302.","DOI":"10.1093\/oxfordjournals.annonc.a057939"},{"key":"2019111708422702800_R41","doi-asserted-by":"crossref","unstructured":"Erdkamp FL, Breed WP, Bosch LJ, Wijnen JT, Blijham GB. Hodgkin disease in the elderly. A registry-based analysis. Cancer. 1992;70:830\u2013834.","DOI":"10.1002\/1097-0142(19920815)70:4<830::AID-CNCR2820700418>3.0.CO;2-X"},{"key":"2019111708422702800_R42","doi-asserted-by":"crossref","unstructured":"Kennedy BJ, Loeb V, Jr., Peterson V, Donegan W, Natarajan N, Mettlin C. Survival in Hodgkin\u2019s disease by stage and age. Med Pediatr Oncol. 1992;20:100\u2013104.","DOI":"10.1002\/mpo.2950200203"},{"key":"2019111708422702800_R43","doi-asserted-by":"crossref","unstructured":"Bennett JM, Andersen JW, Begg CB, Glick JH. Age and Hodgkin\u2019s disease: the impact of competing risks and possibly salvage therapy on long term survival: an E.C.O.G. study. Leuk Res. 1993;17:825\u2013832.","DOI":"10.1016\/0145-2126(93)90147-D"},{"key":"2019111708422702800_R44","doi-asserted-by":"crossref","unstructured":"Diaz-Pavon JR, Cabanillas F, Majlis A, Hagemeister FB. Outcome of Hodgkin\u2019s disease in elderly patients. Hematol Oncol. 1995;13:19\u201327.","DOI":"10.1002\/hon.2900130104"},{"key":"2019111708422702800_R45","doi-asserted-by":"crossref","unstructured":"Proctor SJ, Rueffer JU, Angus B, et al. Hodgkin\u2019s disease in the elderly: current status and future directions. Ann Oncol. 2002;13(Suppl 1):133\u2013137.","DOI":"10.1093\/annonc\/13.S1.133"},{"key":"2019111708422702800_R46","doi-asserted-by":"crossref","unstructured":"Stark GL, Wood KM, Jack F, Angus B, Proctor SJ, Taylor PR. Hodgkin\u2019s disease in the elderly: a population-based study. Br J Haematol. 2002;119:432\u2013440.","DOI":"10.1046\/j.1365-2141.2002.03815.x"},{"key":"2019111708422702800_R47","doi-asserted-by":"crossref","unstructured":"Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin\u2019s disease. International Prognostic Factors Project on Advanced Hodgkin\u2019s Disease. N Engl J Med. 1998;339:1506\u20131514.","DOI":"10.1056\/NEJM199811193392104"},{"key":"2019111708422702800_R48","unstructured":"Klimm B, Diehl V, Engert A. Hodgkin\u2019s lymphoma in the elderly: a different disease in patients over 60. Oncology (Williston Park).2007;21:982\u2013990; discussion 90, 96, 98 passim."},{"key":"2019111708422702800_R49","doi-asserted-by":"crossref","unstructured":"Feltl D, Vitek P, Zamecnik J. Hodgkin\u2019s lymphoma in the elderly: the results of 10 years of follow-up. Leuk Lymphoma. 2006;47:1518\u20131522.","DOI":"10.1080\/10428190500518602"},{"key":"2019111708422702800_R50","doi-asserted-by":"crossref","unstructured":"Engert A, Ballova V, Haverkamp H, et al. Hodgkin\u2019s lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin\u2019s Study Group. J Clin Oncol. 2005;23:5052\u20135060.","DOI":"10.1200\/JCO.2005.11.080"},{"key":"2019111708422702800_R51","doi-asserted-by":"crossref","unstructured":"Kim HK, Silver B, Li S, Neuberg D, Mauch P. Hodgkin\u2019s disease in elderly patients (> or =60): clinical outcome and treatment strategies. Int J Radiat Oncol Biol Phys. 2003;56:556\u2013560.","DOI":"10.1016\/S0360-3016(02)04596-0"},{"key":"2019111708422702800_R52","doi-asserted-by":"crossref","unstructured":"Macpherson N, Klasa RJ, Gascoyne R, O\u2019Reilly SE, Voss N, Connors JM. Treatment of elderly Hodgkin\u2019s lymphoma patients with a novel 5-drug regimen (ODBEP): a phase II study. Leuk Lymphoma. 2002;43:1395\u20131402.","DOI":"10.1080\/10428190290033332"},{"key":"2019111708422702800_R53","doi-asserted-by":"crossref","unstructured":"Levis A, Pietrasanta D, Anselmo AP, Ambrosetti A, Bertini M. Treatment of elderly Hodgkin\u2019s lymphoma patients. The experience of the Italian Lymphoma Intergroup. Tumori. 2002;88(1 Suppl 1):S29\u201331.","DOI":"10.1177\/030089160208800109"},{"key":"2019111708422702800_R54","unstructured":"Landgren O, Algernon C, Axdorph U, et al. Hodgkin\u2019s lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica. 2003;88:438\u2013444."},{"key":"2019111708422702800_R55","doi-asserted-by":"crossref","unstructured":"Weekes CD, Vose JM, Lynch JC, et al. Hodgkin\u2019s disease in the elderly: Improved treatment outcome with a doxorubicin-containing regimen. J Clin Oncol;2002;20:1087\u20131093.","DOI":"10.1200\/JCO.20.4.1087"},{"key":"2019111708422702800_R56","unstructured":"Levis A, Depaoli L, Bertini M, et al. Results of a low aggressivity chemotherapy regimen (CVP\/CEB) in elderly Hodgkin\u2019s disease patients. Haematologica. 1996;81:450\u2013456."},{"key":"2019111708422702800_R57","unstructured":"Zinzani PL, Magagnoli M, Bendandi M, et al. Efficacy of the VBM regimen in the treatment of elderly patients with Hodgkin\u2019s disease. Haematologica. 2000;85:729\u2013732."},{"key":"2019111708422702800_R58","doi-asserted-by":"crossref","unstructured":"Levis A, Anselmo AP, Ambrosetti A, et al. VEPEMB in elderly Hodgkin\u2019s lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol. 2004;15:123\u2013128.","DOI":"10.1093\/annonc\/mdh012"},{"key":"2019111708422702800_R59","doi-asserted-by":"crossref","unstructured":"Ballova V, Ruffer JU, Haverkamp H, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin\u2019s disease comparing BEACOPP baseline and COPP-ABVD (study HD9 elderly). Ann Oncol. 2005;16:124\u2013131.","DOI":"10.1093\/annonc\/mdi023"},{"key":"2019111708422702800_R60","doi-asserted-by":"crossref","unstructured":"Engert A, Pluetschow A, Eich HT, et al. Combined modality treatment of two or four cycles of ABVD followed by involved field radiotherapy in the treatment of patients with early stage Hodgkin\u2019s lymphoma: updated interim analysis of the randomised HD10 Study of the German Hodgkin Study Group (GHSG) [abstract]. Blood. 2005;106. Abstract #2673.","DOI":"10.1182\/blood.V106.11.2673.2673"},{"key":"2019111708422702800_R61","doi-asserted-by":"crossref","unstructured":"Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin\u2019s disease: long-term results. J Clin Oncol. 2004;22:2835\u20132841.","DOI":"10.1200\/JCO.2004.12.170"},{"key":"2019111708422702800_R62","doi-asserted-by":"crossref","unstructured":"Klimm B, Eich HT, Haverkamp H, et al. Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin\u2019s lymphoma: an analysis from the German Hodgkin Study Group. Ann Oncol. 2007;18:357\u2013363.","DOI":"10.1093\/annonc\/mdl379"},{"key":"2019111708422702800_R63","doi-asserted-by":"crossref","unstructured":"Kolstad A, Nome O, Delabie J, Lauritzsen GF, Fossa A, Holte H. Standard CHOP-21 as first line therapy for elderly patients with Hodgkin\u2019s lymphoma. Leuk Lymphoma. 2007;48:570\u2013576.","DOI":"10.1080\/10428190601126610"},{"key":"2019111708422702800_R64","doi-asserted-by":"crossref","unstructured":"Canellos GP, Duggan D, Johnson J, Niedzwiecki D. How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? J Clin Oncol. 2004;22:1532\u20131533.","DOI":"10.1200\/JCO.2004.99.010"},{"key":"2019111708422702800_R65","doi-asserted-by":"crossref","unstructured":"Proctor SJ, Wilkinson J. A web-based study concept designed to progress clinical research for \u2018orphan\u2019 disease areas in haematological oncology in the elderly: the SHIELD programme. Crit Rev Oncol Hematol. 2007;61:79\u201383.","DOI":"10.1016\/j.critrevonc.2006.07.002"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2008\/1\/334\/786520\/334_339ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2008\/1\/334\/786520\/334_339ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T14:06:07Z","timestamp":1632751567000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2008\/1\/334\/95834\/Challenging-Problems-Coincident-Pregnancy-HIV"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,1]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2008.1.334","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,1]]}}}